Cancer Research Technology
Log in Register
Menu

Info

Catalogue Number 151146
Applications FACS IHC IF IP WB
Antigen/Gene or Protein Targets p53
Reactivity Chicken and Mammalian
Relevance Monoclonal antibody reacts specifically with mutated p53 at an epitope conserved across species and normally hidden within the protein structure in non-mutant forms.

Background and Research Application
Anti-p53 (Pab 240) antibody recognises an evolutionary conserved epitope upon p53 hidden within the normal protein structure, however it does not bind to immunoprecipitated wild type p53. This antibody recognises an epitope which is structurally elusive when p53 is in a wildtype conformation but becomes accessible upon denaturation or through mutational conformations where point mutations within the TP53 gene alter the conformational structure of the protein. p53 is a stress-regulated transcription factor that regulates cell cycle arrest and was first identified as an SV40 large T antigen-binding protein. p53 is the most common genetic mutational event in so far identified in human cancers, with the gene present on the short arm of chromosome 17 – a frequent site of allele loss in common cancers. The structure of p53 comprises an N-terminal transactivation domain, a central DNA-binding domain, an oligomerisation domain, and a C-terminal regulatory domain. p53 is a tumour suppressor which upregulates growth arrest and apoptosis-related genes in response to stress signals, thereby influencing programmed cell death, cell differentiation, and cell cycle control mechanisms.
Anti-p53 Pab 240 was created further understand the biochemical role of p53 in cancers and the precise effects of mutation.
Host Mouse
Immunogen A gel purified p53-b-galactosidase fusion protein containing p53 sequence from amino acids 14-389 (derived from the pSV53C p53 cDNA clone)
Immunogen UniProt ID P04637
Positive Control MDA-MB-231 cell line
Subclass IgG1 kappa
Molecular Weight (kDa) 53
Myeloma Used Sp2/0-Ag14
Recommended Growing Conditions RPMI 1640 + 7.5% FCS
Strain Balb/c
Notes
RECENTLY UPDATED
Production Details
Purified using multi-step affinity chromatography with protein A.

Storage Conditions
Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles.

Points of Interest
Detection of p53 using PAb 240: 50% colon cancer sections are positive, 30% of breast cancer sections and 70% of lung cancer sections. Normal and premalignant tissue are negative.

Immunoprecipitation with anti-p53 Pab 240 is a possible diagnostic for mutation within p53. It is thought that different point mutations which convert p53 from a recessive to a dominant oncogene exert a common conformational effect to the protein, which prevents (SV40) T antigen binding and promotes self-oligomerisation. Anti-p53 Pab 240 cannot bind to p53 when it is bound to SV40 T antigen. p53 must be unfolded or ‘melted’ from its normal 3D structure, as in most p53 mutants, to react with Pab240.
This antibody was selected for further study given it reacts with human, mouse, rat, hamster, bovine and chicken p53 in immunoblotting experiments. It can stain both the nuclei and cytoplasm, a key indicator of the presence of mutant p53 as typically wild-type p53 is only present within the nucleus.

Concentration
1mg/ml as standard

Difference Between Clones
Pab 246 binds to wild type p53, whereas pab240 binds to mutated or denatured p53.
Research Area Apoptosis and Programmed Cell Death, Cancer, Cell Cycle, DNA Damage and Repair, Epigenetics & Nuclear Signalling

References

There are 22 reference entries for this reagent.

View All References

References: 22 entries

Renzi et al. 2019. PLoS One. 14(4):e0215621. PMID: 30998743.

Diaz Osterman et al. 2019. Elife. 8:. PMID: 31478830.

Fekry et al. 2018. Nat Commun. 9(1):4149. PMID: 30297838.

Katz et al. 2018. Genes Dev. 32(5-6):430-447. PMID: 29549180.

Chen et al. 2017. Br J Pharmacol. 174(23):4345-4361. PMID: 28910492.

İlhan et al. 2016. J Vet Diagn Invest. :. PMID: 27016721.

Expression of p53 protein, Jaagsiekte sheep retrovirus matrix protein, and surfactant protein in the lungs of sheep with pulmonary adenomatosis.

Europe PMC ID: 27016721

Jakobsen et al. 2015. J Extracell Vesicles. 4:26659. PMID: 25735706.

Exosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma.

Europe PMC ID: 25735706

Pan et al. 2009. EMBO J. 28(22):3500-13. PMID: 19745809.

SnoN functions as a tumour suppressor by inducing premature senescence.

Europe PMC ID: 19745809

Said et al. 1992. Am J Pathol. 141(6):1343-8. PMID: 1466398.

Immunohistochemical analysis of p53 expression in malignant lymphomas.

Europe PMC ID: 1466398

Walker et al. 1991. J Pathol. 165(3):203-11. PMID: 1684809.

Expression of p53 protein in infiltrating and in-situ breast carcinomas.

Europe PMC ID: 1684809

Bártek et al. 1991. Oncogene. 6(9):1699-703. PMID: 1923535.

Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.

Europe PMC ID: 1923535

Gannon et al. 1990. EMBO J. 9(5):1595-602. PMID: 1691710.

Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.

Europe PMC ID: 1691710

Iggo et al. 1990. Lancet. 335(8691):675-9. PMID: 1969059.

Increased expression of mutant forms of p53 oncogene in primary lung cancer.

Europe PMC ID: 1969059

Greaves. R. F (1988) Ph.D Thesis. University of London.


Add a reference

References: 22 entries

Renzi et al. 2019. PLoS One. 14(4):e0215621. PMID: 30998743.

Diaz Osterman et al. 2019. Elife. 8:. PMID: 31478830.

Fekry et al. 2018. Nat Commun. 9(1):4149. PMID: 30297838.

Katz et al. 2018. Genes Dev. 32(5-6):430-447. PMID: 29549180.

Chen et al. 2017. Br J Pharmacol. 174(23):4345-4361. PMID: 28910492.

İlhan et al. 2016. J Vet Diagn Invest. :. PMID: 27016721.

Expression of p53 protein, Jaagsiekte sheep retrovirus matrix protein, and surfactant protein in the lungs of sheep with pulmonary adenomatosis.

Jakobsen et al. 2015. J Extracell Vesicles. 4:26659. PMID: 25735706.

Exosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma.

Pan et al. 2009. EMBO J. 28(22):3500-13. PMID: 19745809.

SnoN functions as a tumour suppressor by inducing premature senescence.

Said et al. 1992. Am J Pathol. 141(6):1343-8. PMID: 1466398.

Immunohistochemical analysis of p53 expression in malignant lymphomas.

Walker et al. 1991. J Pathol. 165(3):203-11. PMID: 1684809.

Expression of p53 protein in infiltrating and in-situ breast carcinomas.

Bártek et al. 1991. Oncogene. 6(9):1699-703. PMID: 1923535.

Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.

Gannon et al. 1990. EMBO J. 9(5):1595-602. PMID: 1691710.

Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.

Iggo et al. 1990. Lancet. 335(8691):675-9. PMID: 1969059.

Increased expression of mutant forms of p53 oncogene in primary lung cancer.

Greaves. R. F (1988) Ph.D Thesis. University of London.


Add a reference